scispace - formally typeset
Open AccessJournal ArticleDOI

Ventilator-associated pneumonia in critically ill patients with COVID-19 infection: a narrative review

Sean Boyd, +3 more
- 05 May 2022 - 
- Vol. 8, Iss: 3, pp 00046-2022
TLDR
Critically ill COVID-19 patients are at risk of developing VAP for several reasons, which increases their overall mortality, and it is recommended to recommend the use of invasive techniques when possible.
Abstract
COVID pneumonitis can cause patients to become critically ill. They may require intensive care and mechanical ventilation. Ventilator-associated pneumonia (VAP) is a concern. This review discusses VAP in this group. Several reasons have been proposed to explain the elevated rates of VAP in critically ill COVID patients compared to non-COVID patients. Extrinsic factors include understaffing, lack of personal protective equipment and use of immunomodulating agents. Intrinsic factors include severe parenchymal damage and immune dysregulation, along with pulmonary vascular endothelial inflammation and thrombosis. The rate of VAP has been reported at 45.4%, with an intensive care unit mortality rate of 42.7%. Multiple challenges to diagnosis exist. Other conditions such as acute respiratory distress syndrome, pulmonary oedema and atelectasis can present with similar features. Frequent growth of gram-negative bacteria has been shown in multiple studies, with particularly high rates of Pseudomonas aeruginosa. The rate of invasive pulmonary aspergillosis has been reported at 4–30%. We would recommend the use of invasive techniques when possible. This will enable de-escalation of antibiotics as soon as possible, decreasing overuse. It is also important to keep other possible causes of VAP in mind, e.g. COVID-19-associated pulmonary aspergillosis or cytomegalovirus. Diagnostic tests such as galactomannan and β-D-glucan should be considered. These patients may face a long treatment course, with risk of re-infection, along with prolonged weaning, which carries its own long-term consequences. Critically ill COVID-19 patients are at risk of developing VAP for several reasons. This increases their overall mortality. Although challenging, early identification of the causative organism through invasive techniques is advised. https://bit.ly/3vCatYv

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Effect of SARS-CoV-2 infection and pandemic period on healthcare-associated infections acquired in intensive care units

TL;DR: In this paper , the authors compared the occurrence of healthcareassociated infections acquired in intensive care units (HAI-ICUs) in France among patients with COVID-19 and those without it in 2020 and the latter with that in patients before the COVID19 pandemic.
Journal ArticleDOI

Impact of outdoor air pollution on severity and mortality in COVID-19 pneumonia

TL;DR: In this article , the authors examined the relationship between exposure to outdoor air pollution and the risk of death in patients with COVID-19 pneumonia using individual-level data and investigated the impact of air pollutants on gas exchange and systemic inflammation in this disease.
Journal ArticleDOI

Bacterial pneumonia associated with multidrug-resistant Gram-negative pathogens: Understanding epidemiology, resistance patterns, and implications with COVID-19

TL;DR: In this article , the authors focus on the epidemiology of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), and present the roles and the antimicrobial resistance patterns of implicated multidrug-resistant (MDR) Gram-negative pathogens such as carbapenem-resistant Acinetobacter baumannii (CRAB), CARP-resistant Pseudomonas aeruginosa (CRPA), as well as colistin-resistant Gramnegative pathogens and extended-spectrum β-lactamase (ESBL)-producing Enterobacterales.
References
More filters
Journal ArticleDOI

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19.

TL;DR: In this small series, vascular angiogenesis distinguished the pulmonary pathobiology of Covid-19 from that of equally severe influenza virus infection.
Journal ArticleDOI

Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society

TL;DR: These guidelines are intended for use by healthcare professionals who care for patients at risk for hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), including specialists in infectious diseases, pulmonary diseases, critical care, and surgeons, anesthesiologists, hospitalists, and any clinicians and healthcare providers caring for hospitalized patients with nosocomial pneumonia.
Related Papers (5)